Danish pharmaceutical giant Novo Nordisk announced on November 10 that it plans to invest over 42 billion Danish kroner (approximately 6 billion US dollars) starting this year to expand its existing production facilities in Kalundborg, Denmark, for its current and future portfolio of serious chronic disease products.
Novo Nordisk stated that the investment will create more capacity for the entire global value chain, from active pharmaceutical ingredient (API) production to packaging, "with the vast majority of the investment being used for API capacity." The statement noted that this investment, which includes GLP-1 products, will enhance Novo Nordisk's ability to meet future market demands.
Novo Nordisk stated that the construction project will be gradually completed from the end of 2025 to 2029, and will create more than 8,000 new jobs upon completion.